Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer

Umemura, Shigeki; Segawa, Yoshihiko; Ueoka, Hiroshi; Hotta, Katsuyuki; Kiura, Katsuyuki; Takigawa, Nagio; Tabata, Masahiro; Bessho, Akihiro; Shinkai, Tetsu; Tanimoto, Mitsune

doi:10.1007/s00432-007-0196-y

Cited by 6 publications

(4 citation statements)

References 31 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in line with our results, plasma ADM has been correlated with tumor progression in neuroendocrine carcinomas of various origin [ 40 ]. With regard to copeptin, a surrogate marker for AVP, our findings are consistent with Umemura et al [ 41 ], investigating mature serum AVP in 34 patients with SCLC where increased levels were associated with reduced survival. It is unclear whether AVP is actively involved in carcinogenesis, although an indirect effect on angiogenesis by stimulated secretion of VEGF and endothelin-1 was suggested in vitro [ 42 , 43 ].…”

Section: Discussionsupporting

confidence: 91%

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)

Gezelius

Bendahl

Gallo

et al. 2022

Cancers

View full text Add to dashboard Cite

Cardiovascular comorbidity is common in small cell lung cancer (SCLC) and may significantly affect treatment tolerability and patient outcome. Still, there are no established biomarkers for objective and dynamic assessment as a tool for improved treatment decisions. We have investigated circulating levels of midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial-natriuretic peptide (MR-proANP), copeptin (surrogate for vasopressin) and suppression-of-tumorigenicity-2 (ST2), all known to correlate with various aspects of cardiovascular function, in a SCLC cohort (N = 252) from a randomized, controlled trial (RASTEN). For all measured biomarkers, protein levels were inversely associated with survival, particularly with ST2 and MR-proADM, where the top versus bottom quartile was associated with an adjusted hazard ratio of 2.40 (95% CI 1.44–3.98; p = 0.001) and 2.18 (95% CI 1.35–3.51; p = 0.001), respectively, in the entire cohort, and 3.43 (95% CI 1.73–6.79; p < 0.001) and 3.49 (95% CI 1.84–6.60; p < 0.001), respectively, in extensive disease patients. A high combined score of MR-proADM and ST2 was associated with a significantly reduced median OS of 7.0 months vs. 14.9 months for patients with a low combined score. We conclude that the cardiovascular biomarkers MR-proADM and ST2 strongly correlate with survival in SCLC, warranting prospective studies on the clinical utility of MR-proADM and ST2 for improved, individualized treatment decisions.

show abstract

Section: Discussionsupporting

confidence: 91%

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)

Gezelius

Bendahl

Gallo

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In lung cancer, many authors also identified hyponatremia as an independent negative risk factor [30,32,[34][35]. At the same time, Umemura and colleagues found that vasopressin (AVP) is a better prognostic factor than sodium levels [51]. We could confirm that hyponatremia is significantly associated with worse overall survival rates in lung cancer patients.…”

Section: Discussionmentioning

confidence: 60%

Prevalence and Prognostic Significance of Hyponatremia in Lung Cancer Patients: Systematic Review and Meta-Analysis

Bartalis¹,

Gergics²,

Tinusz³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The prevalence of hyponatremia is highly variable among lung cancer patients. It is also an important predictive factor, according to numerous studies. However, its prevalence and prognostic significance in subgroups of lung cancer patients, e.g. in small cell and non-small cell lung cancers (SCLC and NSCLC, respectively), have not yet been evaluated in a meta-analysis.Methods We report this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2009) Statement. We have registered our meta-analysis and review’s protocol to the PROSPERO International Prospective Register of Systematic Reviews, with the following registration number: CRD42020167013. A systematic search was done in the following sources: MEDLINE, Embase, CENTRAL, Web of Science, ClinicalTrials.gov, a WHO Global Health Library. We extracted the effect measure for each outcome as the relative risk (RR) with the related 95% confidence interval (CI). Results We identified a total of 8127 potentially eligible studies and we included 25 studies in our evaluation. The prevalence of hyponatremia in lung cancer patients varied between 3% and 56.1% with an average of 23% without any significant differences between the following subgroups: cancer type (p=0.780), gender (p=0.223), age (p=0.773), ECOG state (p=0.317) and the extent of disease (p=0.999). Hyponatremia was more consistently an independent prognostic factor in NSCLC than in SCLC. The overall survival (OS) was significantly lower in hyponatremic compared to normonatremic patients at 10 months (RR: 0.59, 95% CI, 0.47 to 0.74, p<0.001) and at 20 months (RR: 0.44, 95% CI, 0.33 to 0.59, p<0.001), with worse survival rates in NSCLC than in SCLC (27% vs 42%) (p<0.001). If hyponatremia was corrected, OS at 10 months was 1.83 times higher than in the uncorrected hyponatremia group (95% CI, 1.37 to 2.44, p<0.001), but at 20 months no statistically significant difference could be found between these subgroups (p=0.067).Conclusions Low serum sodium levels have a negative impact on mortality at 10 and 20 months, which is more pronounced among NSCLC patients. The correction of hyponatremia has a positive effect on OS rates at 10 months, but this advantage disappears by 20 months.

show abstract

“…Most studies of the presence of hyponatremia have been published 15-20 years ago. Some large retrospective studies have shown the presence of hyponatremia to be a negative prognostic factor [2][3][4][5][6], while it was not found to be a statistical significant factor in others [7][8][9][10]. It is possible that some stage migration may have taken place during the period studied and that this may have influenced the results.…”

Section: Discussionmentioning

confidence: 85%

The occurrence of hyponatremia in SCLC and the influence on prognosis

2010

View full text Add to dashboard Cite

Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer

Abstract: The data from the current study suggested that serum LDH level and PS were the poor prognostic factors for ED-SCLC. But we additionally identified the prognostic significance of serum AVP level, which may be a more useful factor than serum-sodium level.

Cited by 6 publications

References 31 publications

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)

Prevalence and Prognostic Significance of Hyponatremia in Lung Cancer Patients: Systematic Review and Meta-Analysis

The occurrence of hyponatremia in SCLC and the influence on prognosis

Contact Info

Product

Resources

About